Niagen Bioscience (NAGE) Insider Wendy Buys 31,746 Shares

Insider Buying and Selling at Niagen Bioscience, Inc.

On June 24, 2026, Yu Wing Tak Wendy bought 31,746 shares of Niagen Bioscience, trading under the ticker NAGE on the NasdaqCM. This purchase reflects a significant move by the insider at a price of $3.42 per share, aligning with the stock's recent performance.

What Changed in Insider Holdings

This transaction marks Yu Wing Tak Wendy's continued investment in Niagen Bioscience, increasing their stake with this purchase. The acquisition adds to the confidence shown by other insiders on the same day, as multiple individuals bought the same number of shares, indicating a collective belief in the company’s future prospects.

Other Insiders Joining the Move

On June 24, 2026, several other insiders also acquired 31,746 shares each of Niagen Bioscience. Hamed Shahbazi, Steven Rubin, Kristin Patrick, Ann Cohen, and Ng Wang Yu Gary all made similar purchases, suggesting a shared optimism about the company’s direction. Each insider's purchase reflects a commitment to the firm, which operates in the consumer defensive sector.

Stock Performance Context

The stock closed at $3.42 on the day of these insider trades, which is close to its 52-week low of $2.87. This price point may represent an attractive entry for insiders, especially considering the previous close of $2.99. With a market cap of about $240.5 million, Niagen Bioscience is navigating a challenging revenue growth period, having reported a decline of 4.3% recently.

What NAGE Does

Niagen Bioscience, Inc. focuses on developing products that promote healthy aging. The company’s primary offerings include dietary supplements that feature its proprietary ingredients. It also provides NAD+ precursor nicotinamide riboside, marketed under the NIAGEN brand. This recent insider activity may signal a belief in the company's long-term growth potential as it continues to innovate in the health and wellness space.

What’s Next for Niagen Bioscience

Looking ahead, investors will want to watch for Niagen Bioscience’s next earnings report scheduled for November 3, 2026. The insider transactions reported here reflect positions as of June 24, 2026, and may not represent current holdings, but they do highlight an active interest from the company's leadership.